Business Context and Reporting Period
This Form 8-K Current Report was filed by ReShape Lifesciences Inc. (trading symbol: RSLS) on June 28, 2021. The company, formerly known as Obalon Therapeutics, Inc., is incorporated in Delaware and lists its common stock on The Nasdaq Capital Market. The filing details a material definitive agreement entered into on the report date regarding a warrant exercise and private placement.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $46 million from the warrant exercise and sale of new warrants.
- Debt Repayment: Approximately $10.8 million of net proceeds was used to repay in full the outstanding principal and accrued interest under a secured credit agreement dated March 25, 2020.
- Capital Raised Structure: Investors exercised existing warrants to purchase 7.9 million shares of common stock. In consideration, they received new unregistered warrants to purchase 5.9 million shares (75% of the shares issued).
- Warrant Pricing: The exercise price for both the existing warrants (reduced) and new warrants is $6.00 per share. Investors paid $0.09375 per share for the new warrants.
- Transaction Fees: Maxim Group LLC served as the exclusive placement agent, receiving a cash fee equal to 7.0% of gross proceeds.
Material Changes and Liquidity Impact
The primary material change is the significant improvement in liquidity and balance sheet strength. The company generated approximately $46 million in gross proceeds, a substantial influx of capital compared to prior periods. Crucially, the company utilized a portion of these funds to eliminate its secured debt obligation entirely, removing the associated interest expense and principal repayment burden. The remainder of the net proceeds is designated for working capital and general corporate purposes.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The company intends to use the remaining net proceeds to support working capital needs, suggesting a focus on operational stability and growth initiatives. The company agreed to file a resale registration statement on Form S-3 within 30 days for the new warrants and underlying shares.
Risks and Contingencies:
- Dilution: The transaction involves the issuance of 7.9 million shares immediately and the potential issuance of 5.9 million additional shares upon exercise of new warrants.
- Ownership Limitations: A beneficial ownership limitation prevents any investor from owning more than 9.99% of the outstanding common stock.
- Regulatory Status: The new warrants were offered in a private placement to accredited investors and are not registered under the Securities Act, restricting their resale until registration is effective.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the 7.0% placement agent fee and other offering expenses.
- Confirm the filing of the Form S-3 resale registration statement within the 30-day window.
- Review the updated capitalization table to assess the dilution impact of the 7.9 million shares issued and the 5.9 million shares underlying the new warrants.
- Check subsequent filings for any changes to the company's working capital position or new debt obligations.